Our overall survival analysis results suggest that CDCA3 overexpression may be a predictive biomarker in multiple cancers, including ACC, KIRC, KIRP, LGG, LIHC, LUAD, MESO, PAAD, SARC, and SKCM. This evidence concerns the gene CDCA3 and pancreatic adenocarcinoma.